AU708460B2 - A polynucleotide herpes virus vaccine - Google Patents

A polynucleotide herpes virus vaccine Download PDF

Info

Publication number: AU708460B2
Authority: AU; Australia
Prior art keywords: hsv; dna; polynucleotide; dna plasmid; genes
Prior art date: 1994-07-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU31012/95A

Other languages

English (en)

Other versions

AU3101295A (en

Inventor

Marcy E. Armstrong

Robert D. Keys

John A. Lewis

Margaret A. Liu

William L. Mcclements

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck and Co Inc

Original Assignee

Merck and Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-22

Filing date

1995-07-18

Publication date

1999-08-05

1995-07-18 Application filed by Merck and Co Inc filed Critical Merck and Co Inc

1996-02-22 Publication of AU3101295A publication Critical patent/AU3101295A/en

1997-09-26 Priority to AU45955/97A priority Critical patent/AU738835B2/en

1999-08-05 Application granted granted Critical

1999-08-05 Publication of AU708460B2 publication Critical patent/AU708460B2/en

2015-07-18 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

108091033319 polynucleotide Proteins 0.000 title claims description 45
102000040430 polynucleotide Human genes 0.000 title claims description 45
239000002157 polynucleotide Substances 0.000 title claims description 45
229940124841 Herpesvirus vaccine Drugs 0.000 title description 3
108090000623 proteins and genes Proteins 0.000 claims description 138
102000004169 proteins and genes Human genes 0.000 claims description 58
239000013612 plasmid Substances 0.000 claims description 44
229960005486 vaccine Drugs 0.000 claims description 41
241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 36
230000028993 immune response Effects 0.000 claims description 36
230000001681 protective effect Effects 0.000 claims description 21
238000000034 method Methods 0.000 claims description 20
101710130522 mRNA export factor Proteins 0.000 claims description 15
241000251539 Vertebrata <Metazoa> Species 0.000 claims description 11
230000003622 anti-hsv Effects 0.000 claims description 10
238000013518 transcription Methods 0.000 claims description 7
230000035897 transcription Effects 0.000 claims description 7
230000001939 inductive effect Effects 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
108700026244 Open Reading Frames Proteins 0.000 claims description 5
230000003308 immunostimulating effect Effects 0.000 claims description 5
230000005030 transcription termination Effects 0.000 claims description 5
108010065805 Interleukin-12 Proteins 0.000 claims description 4
102000013462 Interleukin-12 Human genes 0.000 claims description 4
210000001744 T-lymphocyte Anatomy 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
238000013519 translation Methods 0.000 claims description 4
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 3
230000000139 costimulatory effect Effects 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
230000002519 immonomodulatory effect Effects 0.000 claims description 2
102000014150 Interferons Human genes 0.000 claims 1
108010050904 Interferons Proteins 0.000 claims 1
229940079322 interferon Drugs 0.000 claims 1
108020004414 DNA Proteins 0.000 description 103
241000700584 Simplexvirus Species 0.000 description 88
241001465754 Metazoa Species 0.000 description 60
210000004027 cell Anatomy 0.000 description 45
239000013598 vector Substances 0.000 description 44
241000699670 Mus sp. Species 0.000 description 42
241000700605 Viruses Species 0.000 description 37
230000014509 gene expression Effects 0.000 description 35
238000002965 ELISA Methods 0.000 description 25
150000007523 nucleic acids Chemical class 0.000 description 23
238000002347 injection Methods 0.000 description 21
239000007924 injection Substances 0.000 description 21
102000039446 nucleic acids Human genes 0.000 description 21
108020004707 nucleic acids Proteins 0.000 description 21
238000002649 immunization Methods 0.000 description 20
208000015181 infectious disease Diseases 0.000 description 20
230000003053 immunization Effects 0.000 description 18
239000012634 fragment Substances 0.000 description 17
210000001519 tissue Anatomy 0.000 description 16
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 15
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
108010006025 bovine growth hormone Proteins 0.000 description 14
239000013604 expression vector Substances 0.000 description 14
239000011780 sodium chloride Substances 0.000 description 14
238000002474 experimental method Methods 0.000 description 13
239000000047 product Substances 0.000 description 13
230000004083 survival effect Effects 0.000 description 13
238000002255 vaccination Methods 0.000 description 11
241000700198 Cavia Species 0.000 description 10
230000034994 death Effects 0.000 description 10
231100000517 death Toxicity 0.000 description 10
238000010790 dilution Methods 0.000 description 10
239000012895 dilution Substances 0.000 description 10
108091008146 restriction endonucleases Proteins 0.000 description 10
230000002103 transcriptional effect Effects 0.000 description 10
210000003501 vero cell Anatomy 0.000 description 10
108091007433 antigens Proteins 0.000 description 9
102000036639 antigens Human genes 0.000 description 9
230000004044 response Effects 0.000 description 9
108010084884 GDP-mannose transporter Proteins 0.000 description 8
208000009889 Herpes Simplex Diseases 0.000 description 8
239000000427 antigen Substances 0.000 description 8
230000002163 immunogen Effects 0.000 description 8
210000002966 serum Anatomy 0.000 description 8
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 8
230000003612 virological effect Effects 0.000 description 8
108091003079 Bovine Serum Albumin Proteins 0.000 description 7
108700018351 Major Histocompatibility Complex Proteins 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 7
108010067390 Viral Proteins Proteins 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
238000011161 development Methods 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
238000010255 intramuscular injection Methods 0.000 description 7
239000006166 lysate Substances 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
108090000288 Glycoproteins Proteins 0.000 description 6
102000003886 Glycoproteins Human genes 0.000 description 6
239000012091 fetal bovine serum Substances 0.000 description 6
238000003119 immunoblot Methods 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
231100000518 lethal Toxicity 0.000 description 6
230000001665 lethal effect Effects 0.000 description 6
238000006386 neutralization reaction Methods 0.000 description 6
230000003472 neutralizing effect Effects 0.000 description 6
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
238000001262 western blot Methods 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
241000282412 Homo Species 0.000 description 5
206010046865 Vaccinia virus infection Diseases 0.000 description 5
206010048937 Vaginal lesion Diseases 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
210000000612 antigen-presenting cell Anatomy 0.000 description 5
230000000890 antigenic effect Effects 0.000 description 5
230000003115 biocidal effect Effects 0.000 description 5
230000029087 digestion Effects 0.000 description 5
230000036039 immunity Effects 0.000 description 5
230000010354 integration Effects 0.000 description 5
239000002502 liposome Substances 0.000 description 5
108020004999 messenger RNA Proteins 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
230000009257 reactivity Effects 0.000 description 5
230000010076 replication Effects 0.000 description 5
238000004448 titration Methods 0.000 description 5
238000011282 treatment Methods 0.000 description 5
208000007089 vaccinia Diseases 0.000 description 5
241000700199 Cavia porcellus Species 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 4
238000001712 DNA sequencing Methods 0.000 description 4
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 4
102000011931 Nucleoproteins Human genes 0.000 description 4
108010061100 Nucleoproteins Proteins 0.000 description 4
206010033799 Paralysis Diseases 0.000 description 4
229960000723 ampicillin Drugs 0.000 description 4
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
244000309466 calf Species 0.000 description 4
238000010367 cloning Methods 0.000 description 4
238000010276 construction Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
239000000499 gel Substances 0.000 description 4
206010022000 influenza Diseases 0.000 description 4
238000007918 intramuscular administration Methods 0.000 description 4
229940065638 intron a Drugs 0.000 description 4
229930027917 kanamycin Natural products 0.000 description 4
229960000318 kanamycin Drugs 0.000 description 4
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
229930182823 kanamycin A Natural products 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
239000000902 placebo Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
238000003146 transient transfection Methods 0.000 description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
102000043129 MHC class I family Human genes 0.000 description 3
108091054437 MHC class I family Proteins 0.000 description 3
238000000585 Mann–Whitney U test Methods 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
229930193140 Neomycin Natural products 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
229930182555 Penicillin Natural products 0.000 description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
108091008874 T cell receptors Proteins 0.000 description 3
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
238000000246 agarose gel electrophoresis Methods 0.000 description 3
230000000692 anti-sense effect Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000013592 cell lysate Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
101150029683 gB gene Proteins 0.000 description 3
101150002378 gC gene Proteins 0.000 description 3
101150036031 gD gene Proteins 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
238000010166 immunofluorescence Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000012678 infectious agent Substances 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
230000003902 lesion Effects 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
238000013507 mapping Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
210000000107 myocyte Anatomy 0.000 description 3
229960004927 neomycin Drugs 0.000 description 3
239000002245 particle Substances 0.000 description 3
229940049954 penicillin Drugs 0.000 description 3
230000002516 postimmunization Effects 0.000 description 3
230000002265 prevention Effects 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
229960005322 streptomycin Drugs 0.000 description 3
230000001052 transient effect Effects 0.000 description 3
210000001215 vagina Anatomy 0.000 description 3
229920000936 Agarose Polymers 0.000 description 2
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
238000000729 Fisher's exact test Methods 0.000 description 2
108700007698 Genetic Terminator Regions Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 2
101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
108010059343 MM Form Creatine Kinase Proteins 0.000 description 2
SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 2
241000700159 Rattus Species 0.000 description 2
241000714474 Rous sarcoma virus Species 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
230000024932 T cell mediated immunity Effects 0.000 description 2
108700005077 Viral Genes Proteins 0.000 description 2
150000001413 amino acids Chemical group 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
238000001976 enzyme digestion Methods 0.000 description 2
238000001415 gene therapy Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
208000037797 influenza A Diseases 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000002414 leg Anatomy 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
230000037361 pathway Effects 0.000 description 2
238000002962 plaque-reduction assay Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
229940031626 subunit vaccine Drugs 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000012360 testing method Methods 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
239000005723 virus inoculator Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
101150089247 B7 gene Proteins 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
JUQPZRLQQYSMEQ-UHFFFAOYSA-N CI Basic red 9 Chemical compound [Cl-].C1=CC(N)=CC=C1C(C=1C=CC(N)=CC=1)=C1C=CC(=[NH2+])C=C1 JUQPZRLQQYSMEQ-UHFFFAOYSA-N 0.000 description 1
208000019300 CLIPPERS Diseases 0.000 description 1
108010072454 CTGCAG-specific type II deoxyribonucleases Proteins 0.000 description 1
102000008203 CTLA-4 Antigen Human genes 0.000 description 1
108010021064 CTLA-4 Antigen Proteins 0.000 description 1
229940045513 CTLA4 antagonist Drugs 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
235000003913 Coccoloba uvifera Nutrition 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
101000926206 Homo sapiens Putative glutathione hydrolase 3 proenzyme Proteins 0.000 description 1
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
101900228213 Human herpesvirus 2 Envelope glycoprotein D Proteins 0.000 description 1
241000701069 Human herpesvirus 2 strain G Species 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
108020005350 Initiator Codon Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
238000009004 PCR Kit Methods 0.000 description 1
241000609499 Palicourea Species 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
241000288906 Primates Species 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
240000008976 Pterocarpus marsupium Species 0.000 description 1
102100034060 Putative glutathione hydrolase 3 proenzyme Human genes 0.000 description 1
101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
108010046722 Thrombospondin 1 Proteins 0.000 description 1
102100036034 Thrombospondin-1 Human genes 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
239000007997 Tricine buffer Substances 0.000 description 1
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940038444 antibody-based vaccine Drugs 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
229940052223 basic fuchsin Drugs 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000032823 cell division Effects 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000004940 costimulation Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
108020001096 dihydrofolate reductase Proteins 0.000 description 1
239000013024 dilution buffer Substances 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
206010016165 failure to thrive Diseases 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
101150020597 gG gene Proteins 0.000 description 1
101150055782 gH gene Proteins 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
102000054766 genetic haplotypes Human genes 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
208000010726 hind limb paralysis Diseases 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000002766 immunoenhancing effect Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
108700010900 influenza virus proteins Proteins 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229940090046 jet injector Drugs 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
101150109249 lacI gene Proteins 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
238000001325 log-rank test Methods 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 1
230000037125 natural defense Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229950000964 pepstatin Drugs 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
229940023041 peptide vaccine Drugs 0.000 description 1
230000002688 persistence Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
-1 polypropylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000009711 regulatory function Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
230000005951 type IV hypersensitivity Effects 0.000 description 1
208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Oncology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AU31012/95A 1994-07-22 1995-07-18 A polynucleotide herpes virus vaccine Ceased AU708460B2 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
AU45955/97A AU738835B2 (en)	1994-07-22	1997-09-26	A polynucleotide herpes virus vaccine

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US27945994A	1994-07-22	1994-07-22
US279459		1994-07-22
PCT/US1995/009057 WO1996003510A1 (fr)	1994-07-22	1995-07-18	Vaccin polynucleotidique contre le virus de l'herpes

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
AU45955/97A Division AU738835B2 (en)	1994-07-22	1997-09-26	A polynucleotide herpes virus vaccine

Publications (2)

Publication Number	Publication Date
AU3101295A AU3101295A (en)	1996-02-22
AU708460B2 true AU708460B2 (en)	1999-08-05

Family

ID=23069059

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU31012/95A Ceased AU708460B2 (en)	1994-07-22	1995-07-18	A polynucleotide herpes virus vaccine

Country Status (10)

Country	Link
EP (1)	EP0772680A1 (fr)
JP (1)	JPH10503649A (fr)
AU (1)	AU708460B2 (fr)
CA (1)	CA2195099A1 (fr)
CO (1)	CO4410257A1 (fr)
HR (1)	HRP950412A2 (fr)
IL (1)	IL114576A0 (fr)
WO (1)	WO1996003510A1 (fr)
YU (1)	YU49995A (fr)
ZA (1)	ZA956106B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5849719A (en)	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
US7094767B2 (en)	1994-07-22	2006-08-22	Merck & Co., Inc.	Polynucleotide herpes virus vaccine
AU738835B2 (en) *	1994-07-22	2001-09-27	Merck & Co., Inc.	A polynucleotide herpes virus vaccine
JP2001501101A (ja) *	1996-10-01	2001-01-30	メルクエンドカンパニーインコーポレーテッド	ポリヌクレオチドヘルペスウイルスワクチン
AU4908197A (en) *	1996-10-18	1998-05-15	Valentis, Inc.	Gene expression and delivery systems and uses
WO1998017689A2 (fr) *	1996-10-18	1998-04-30	Valentis Inc.	Expression du gene il-12, systemes d'apport et utilisations
GB9720633D0 (en) *	1997-09-29	1997-11-26	Univ Bristol	BHV-2 vector
WO1999040938A2 (fr) *	1998-02-12	1999-08-19	American Cyanamid Company	Vaccins comprenant l'interleukine 12 et antigene viral de l'herpes
US6867000B2 (en) *	2000-12-07	2005-03-15	Wyeth Holdings Corporation	Method of enhancing immune responses to herpes
US9012349B1 (en)	2013-11-01	2015-04-21	Ut-Battelle Llc	Method of synthesizing bulk transition metal carbide, nitride and phosphide catalysts

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3751664T2 (de) *	1986-08-01	1996-06-05	Commw Scient Ind Res Org	Rekombinanter impfstoff
CA2049287C (fr) *	1989-03-21	2005-03-29	Philip L. Felgner	Expression des sequences polynocleotides exogenes chez un vertebre
ATE123065T1 (de) *	1989-07-07	1995-06-15	Takeda Chemical Industries Ltd	Proteine und deren herstellung.

1995
- 1995-07-12 IL IL11457695A patent/IL114576A0/xx unknown
- 1995-07-18 HR HR08/279,459A patent/HRP950412A2/hr not_active Application Discontinuation
- 1995-07-18 AU AU31012/95A patent/AU708460B2/en not_active Ceased
- 1995-07-18 EP EP95926736A patent/EP0772680A1/fr not_active Withdrawn
- 1995-07-18 WO PCT/US1995/009057 patent/WO1996003510A1/fr not_active Application Discontinuation
- 1995-07-18 JP JP8505831A patent/JPH10503649A/ja not_active Withdrawn
- 1995-07-18 CA CA002195099A patent/CA2195099A1/fr not_active Abandoned
- 1995-07-18 CO CO95031727A patent/CO4410257A1/es unknown
- 1995-07-21 YU YU49995A patent/YU49995A/sh unknown
- 1995-07-21 ZA ZA956106A patent/ZA956106B/xx unknown

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. GEN VIROL (1993) 74(12), 2813-7 *
J. VIROL (1993) 67(1), 613-6 *
J. VIROL (1994) 68(4), 2118-26 *

Also Published As

Publication number	Publication date
WO1996003510A1 (fr)	1996-02-08
IL114576A0 (en)	1995-11-27
EP0772680A1 (fr)	1997-05-14
AU3101295A (en)	1996-02-22
ZA956106B (en)	1996-04-10
HRP950412A2 (en)	1997-10-31
CO4410257A1 (es)	1997-01-09
CA2195099A1 (fr)	1996-02-08
YU49995A (sh)	1998-05-15
JPH10503649A (ja)	1998-04-07

Publication	Publication Date	Title
EP0792358B1 (fr)	2005-06-01	Vaccin polynucleotidique contre la tuberculose
AU701973B2 (en)	1999-02-11	Polynucleotide vaccine for papillomavirus
US5648079A (en)	1997-07-15	Herpes simplex virus glycoprotein B vaccine
US7094767B2 (en)	2006-08-22	Polynucleotide herpes virus vaccine
US7122180B2 (en)	2006-10-17	DNA vectors containing mutated HIV proviruses
AU708460B2 (en)	1999-08-05	A polynucleotide herpes virus vaccine
EP0101655A2 (fr)	1984-02-29	Production de protéines virales de Herpes Simplex
US5837261A (en)	1998-11-17	Viral vaccines
US6673601B1 (en)	2004-01-06	Chimeric lyssavirus nucleic acids and polypeptides
AU738835B2 (en)	2001-09-27	A polynucleotide herpes virus vaccine
WO1998014586A1 (fr)	1998-04-09	Vaccins de polynucleotides contre le virus de l'herpes
NZ539154A (en)	2007-05-31	Nucleic acid constructs useful in the treatment of HPV infection
CA2205175C (fr)	2008-02-19	Vaccin polynucleotidique contre la tuberculose
US7238672B1 (en)	2007-07-03	Chimeric lyssavirus nucleic acids and polypeptides